Nav: Home

Glioblastoma clinical trial shows combined therapy extends life for patients 65 and older

March 15, 2017

(TORONTO, Canada - March 16, 2017) - Treating older patients who have malignant brain cancer with the chemotherapy drug temozolomide plus a short course of radiation therapy extends survival by two months compared to treating with radiation alone, show clinical trial results published today in the New England Journal of Medicine.

For 45% of the study participants, improved survival almost doubled - from 7 months to 13.5 months, says co-principal investigator Normand Laperriere, radiation oncologist at Princess Margaret Cancer Centre, University Health Network. This was linked to a molecular marker that indicated if a DNA repair mechanism against the drug was active. When the mechanism was "off", tumours responded better to treatment.

"Everyone benefited to a varying degree and the study confirmed the predictive nature of the molecular marker in the largest sample to date where the status was known. We anticipate this combined therapy will be the treatment strategy broadly adopted around the world for patients 65 and older because it makes a significant difference in the course of this terrible disease," says Dr. Laperriere, who is also a Professor in the Department of Radiation Oncology, University of Toronto.

The trial was conducted with co-investigators Dr. James Perry, Sunnybrook Health Science and Odette Cancer Centres, Toronto, Dr. Christopher O'Callaghan, Canadian Cancer Trials Group, Kingston, ON, and international collaborators from Europe, Australia, New Zealand, Japan.

From 2007 to 2013, the randomized Phase III clinical trial enrolled 562 patients with glioblastoma, the most common malignant brain cancer in adults. Average age of onset is 65 and there is no cure. The incidence of glioblastoma is increasing in aging societies with half of all patients now 65 or older. In the study, patients ranged in age from 65 to 90; two-thirds were 70 or older.

This was the first study to investigate combining the drug with radiotherapy in older patients. Two previous studies had looked at either the role of the drug alone or the role of radiotherapy alone in treating glioblastoma.

"There has been no clear standard of care for treatment of glioblastoma in the elderly," says Dr. Laperriere. "For patients under 65, the protocol is six weeks of radiation therapy plus the drug, but this regimen is poorly tolerated by older patients."

Temozolomide is an oral chemotherapy (taken as a pill) which is extremely well tolerated, and participants in both arms of the study reported no differences in quality of life. "The drug is so well tolerated, there is no downside in administering it to all glioblastoma patients,'' says Dr. Laperriere. "Thankfully in such a terrible disease, at least we have therapies that are easy on the patient and easy to take."
-end-
The study was funded by the Canadian Cancer Society Research Institute (Canadian Cancer Trials Group), Merck and The Princess Margaret Cancer Foundation.

About Princess Margaret Cancer Centre, University Health Network

The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education; all affiliated with the University of Toronto. For more information, go to http://www.theprincessmargaret.ca or http://www.uhn.ca .

About the Canadian Cancer Trials Group (CCTG)

The CCTG is the only Canadian cooperative cancer trials group conducting the entire range of cancer trials from early phase studies to large international randomized controlled trials across all cancer types. Its primary mission is to assess the effectiveness of interventions to prevent the development of cancer or improve the care of those patients who do develop cancer. It is a national research program of the Canadian Cancer Society. Its Central Operations and Statistics Centre is located at Queen's University in Kingston, Ontario, Canada. For more information on CCTG, please visit https://www.ctg.queensu.ca/.

University Health Network

Related Radiation Therapy Articles:

Radiation therapy, macrophages improve efficacy of nanoparticle-delivered cancer therapy
Massachusetts General Hospital investigators report finding finding how appropriately timed radiation therapy can significantly improve the delivery of cancer nanomedicines by attracting macrophages to tumor blood vessels, which results in a transient 'burst' of nanoencapsulated drugs from capillaries into the tumor.
Moffitt improves radiation therapy for head and neck patients
The researchers are able to use the radiosensitivity index within a mathematical framework to select the optimum radiotherapy dose for each patient based on their individual tumor biology.
As radiation therapy declined so did second cancers in childhood cancer survivors
Childhood cancer survivors are living longer. Now research shows they are also less likely to develop second cancers while still young.
Conventional radiation therapy may not protect healthy brain cells
A new study shows that repeated radiation therapy used to target tumors in the brain may not be as safe to healthy brain cells as previously assumed.
Does radiation therapy improve survival for women with ductal carcinoma in situ?
Investigators from Brigham and Women's Hospital (BWH) and the Dana-Farber Cancer Institute have found that a set of easily measurable risk factors can predict the magnitude of survival benefit offered by radiation therapy following breast cancer surgery.
More Radiation Therapy News and Radiation Therapy Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Teaching For Better Humans
More than test scores or good grades — what do kids need to prepare them for the future? This hour, guest host Manoush Zomorodi and TED speakers explore how to help children grow into better humans, in and out of the classroom. Guests include educators Olympia Della Flora and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...